<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943565</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001850</org_study_id>
    <secondary_id>Hydromorphone_IT</secondary_id>
    <nct_id>NCT01943565</nct_id>
  </id_info>
  <brief_title>Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study</brief_title>
  <official_title>Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain relief after cesarean delivery can be provided in a few ways. Most commonly, certain
      medications called opioids, such as morphine, are given through the vein or into the muscle.
      However, a more effective way to give pain relief with fewer side effects (such as nausea and
      slowing your breathing) is to give opioids in the spinal space as part of the medications
      given for a cesarean delivery.

      For many years, the opioid of choice was morphine due to its long anesthetic effect and
      acceptable side effect profile. A nation-wide disruption in the supply of preservative-free
      morphine has made it necessary to look for alternatives. Many institutions worldwide have
      used another opioid, called hydromorphone, in the spinal space for over a decade. This drug
      has a very good safety and side effect profile and has been used at the investigators'
      institution for more than a year. Of interest, while a number of different doses of
      hydromorphone have been used, there have been very few studies to evaluate the best dose for
      providing good pain relief with minimal side effects. The goal of this study is to find the
      best dose of spinal hydromorphone for women undergoing cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrathecal opioids in have been shown to produce analgesia. Lipid solubility and effect on
      specific mu opioid receptors in the dorsal horn of the spinal cord primarily determine the
      analgesic effect of intrathecally injected opioids. Rostral spread of intrathecal opioids
      causes some of the side effects like pruritus, respiratory depression, nausea and vomiting.

      In the investigators' institute, during cesarean delivery under spinal anesthesia is usually
      performed with 1.6-1.8 ml of 0.75% bupivacaine with dextrose (hyperbaric solution) with
      10-20mcg of fentanyl. Preservative free intrathecal (IT) morphine100 to 200 mcg is injected
      at the time of initiation of spinal block for postoperative pain relief. Multiple studies
      have shown excellent postoperative pain relief following cesarean delivery up to 18hrs with
      this dosing regimen.

      However, there has been a national shortage of preservative free morphine since August 2012.
      Based on the pharmacokinetic and pharmacodynamic profile, intrathecal (IT) preservative free
      hydromorphone 100 mcg has been used as a substitute. Anecdotal experience during the past 8
      months suggest that patients have comparable post partum pain relief, with a similar
      side-effect profile to IT morphine.

      There is no published data on the optimal dose of IT hydromorphone for post cesarean
      analgesia. There are case reports and retrospective case study of use of 100mcg IT
      hydromorphone. One randomized controlled trial for knee arthroscopy used 2.5-5-10 mcg of IT
      hydromorphone for postoperative analgesia.

      Hence it is important to determine the optimal dose of IT hydromorphone for post operative
      pain management following cesarean delivery in terms of analgesic efficacy, incidence of side
      effects and the need for treatment interventions

      This study will aim to determine the optimal dose of intrathecal hydromorphone that would
      provide adequate postoperative analgesia with minimal side effects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Research question answered by another group of researchers (Sviggum et al)
  </why_stopped>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24hr Post-partum IV Opioid Requirement</measure>
    <time_frame>24hrs after administration of intrathecal hydromorphone</time_frame>
    <description>Intrathecal (IT) hydromorphone added to intrathecally administered local anesthetics for spinal anesthesia increases patient comfort by decreasing post-operative pain. This leads to a decrease in the post-operative intravenous hydromorphone requirements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation, Need for Supplemental Oxygen</measure>
    <time_frame>24hrs post administration of IT hydromorphone</time_frame>
    <description>Intravenously, and to a lesser extent, intrathecally administered opioids can lead to respiratory depressions. Therefore the subjects' oxygen saturation is measured (standard clinical practice).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Nausea and Vomiting Requiring Rescue Medication</measure>
    <time_frame>24hrs post administration of IT hydromorphone</time_frame>
    <description>IV and IT opioids can induce nausea and vomiting. Outcome measure is reported as percentage of patients with nausea and vomiting requiring rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hypothermia (Body Temperature &lt; 95F/35C)</measure>
    <time_frame>24hrs post administration of IT hydromorphone</time_frame>
    <description>intrathecally administered opioids can cause hypothermia (body temperature &lt;95F/35C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Visual Disturbances</measure>
    <time_frame>24hrs post administration of IT hydromorphone</time_frame>
    <description>IT/IV opioids can create visual disturbances. The number of patients with visual disturbances are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Pruritus</measure>
    <time_frame>24hrs post administration of IT hydromorphone</time_frame>
    <description>IT opioids can cause pruritus. Persistent pruritus requiring treatment will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Vasopressor Use: Ephedrine Equivalents</measure>
    <time_frame>Intraoperatively (at time of operation)</time_frame>
    <description>IT (intrathecal) applied local anesthetics and opioids can cause arterial and venous vasodilation leading to a decrease in afterload as well as preload. This is typically treated with volume replacement and vasopressors (acutely). Total intraoperative vasopressor use will be reported for ephedrine equivalents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Vasopressor Use: Phenylephrine Equivalents</measure>
    <time_frame>Intraoperatively (at time of operation)</time_frame>
    <description>IT (intrathecal ) applied local anesthetics and opioids can cause arterial and venous vasodilation leading to a decrease in afterload as well as preload. This is typically treated with volume replacement and vasopressors (acutely).
Total intraoperative vasopressor use will be reported for phenylephrine equivalents.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy</condition>
  <condition>Pain</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Hydromorphone 25mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone 50mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone 100mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone 25mcg</intervention_name>
    <description>Intrathecal Hydromorphone 25mcg</description>
    <arm_group_label>Hydromorphone 25mcg</arm_group_label>
    <other_name>HM25</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone 50mcg</intervention_name>
    <description>Intrathecal Hydromorphone 50mcg</description>
    <arm_group_label>Hydromorphone 50mcg</arm_group_label>
    <other_name>HM50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone 100mcg</intervention_name>
    <description>Intrathecal Hydromorphone 100mcg</description>
    <arm_group_label>Hydromorphone 100mcg</arm_group_label>
    <other_name>HM100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spinal anesthesia</intervention_name>
    <description>bupivacaine 0.75% 1.6 mL (12mg)</description>
    <arm_group_label>Hydromorphone 25mcg</arm_group_label>
    <arm_group_label>Hydromorphone 50mcg</arm_group_label>
    <arm_group_label>Hydromorphone 100mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy at-term parturients undergoing elective cesarean delivery under spinal
             anesthesia

        Exclusion Criteria:

          -  Emergency cesarean delivery

          -  Respiratory disease

          -  significant comorbidities: preeclampsia, insulin-dependent diabetes mellitus

          -  obstructive sleep apnea

          -  body mass index &gt; 35kg/m2

          -  &lt;18yrs

          -  documented intolerance or allergy to systemic or neuraxial opioids

          -  patient with a history of chronic opioid or current use of opioids
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk J Varelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979 Feb;50(2):149-51.</citation>
    <PMID>373503</PMID>
  </reference>
  <reference>
    <citation>Ross BK, Hughes SC. Epidural and spinal narcotic analgesia. Clin Obstet Gynecol. 1987 Sep;30(3):552-65. Review.</citation>
    <PMID>2888557</PMID>
  </reference>
  <reference>
    <citation>Palmer CM, Emerson S, Volgoropolous D, Alves D. Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology. 1999 Feb;90(2):437-44. Erratum in: Anesthesiology 1999 Apr;90(4):1241.</citation>
    <PMID>9952150</PMID>
  </reference>
  <reference>
    <citation>Milner AR, Bogod DG, Harwood RJ. Intrathecal administration of morphine for elective Caesarean section. A comparison between 0.1 mg and 0.2 mg. Anaesthesia. 1996 Sep;51(9):871-3.</citation>
    <PMID>8882255</PMID>
  </reference>
  <reference>
    <citation>Lee YS, Park YC, Kim JH, Kim WY, Yoon SZ, Moon MG, Min TJ. Intrathecal hydromorphone added to hyperbaric bupivacaine for postoperative pain relief after knee arthroscopic surgery: a prospective, randomised, controlled trial. Eur J Anaesthesiol. 2012 Jan;29(1):17-21. doi: 10.1097/EJA.0b013e3283476055.</citation>
    <PMID>21562420</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <results_first_submitted>May 22, 2017</results_first_submitted>
  <results_first_submitted_qc>May 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Dirk Varelmann, MD</investigator_full_name>
    <investigator_title>Instructor of Anaesthesiology</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Healthy</keyword>
  <keyword>Intrathecal</keyword>
  <keyword>Opioids</keyword>
  <keyword>Spinal</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Pain</keyword>
  <keyword>Cesarean</keyword>
  <keyword>Delivery</keyword>
  <keyword>Human</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydromorphone 25mcg</title>
          <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
        <group group_id="P2">
          <title>Hydromorphone 50mcg</title>
          <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
        <group group_id="P3">
          <title>Hydromorphone 100mcg</title>
          <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydromorphone 25mcg</title>
          <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
        <group group_id="B2">
          <title>Hydromorphone 50mcg</title>
          <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
        <group group_id="B3">
          <title>Hydromorphone 100mcg</title>
          <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24hr Post-partum IV Opioid Requirement</title>
        <description>Intrathecal (IT) hydromorphone added to intrathecally administered local anesthetics for spinal anesthesia increases patient comfort by decreasing post-operative pain. This leads to a decrease in the post-operative intravenous hydromorphone requirements.</description>
        <time_frame>24hrs after administration of intrathecal hydromorphone</time_frame>
        <population>One 25 mcg patient is missing data on this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>24hr Post-partum IV Opioid Requirement</title>
          <description>Intrathecal (IT) hydromorphone added to intrathecally administered local anesthetics for spinal anesthesia increases patient comfort by decreasing post-operative pain. This leads to a decrease in the post-operative intravenous hydromorphone requirements.</description>
          <population>One 25 mcg patient is missing data on this outcome</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="3.51"/>
                    <measurement group_id="O2" value="3.11" spread="2.15"/>
                    <measurement group_id="O3" value="4.40" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Saturation, Need for Supplemental Oxygen</title>
        <description>Intravenously, and to a lesser extent, intrathecally administered opioids can lead to respiratory depressions. Therefore the subjects' oxygen saturation is measured (standard clinical practice).</description>
        <time_frame>24hrs post administration of IT hydromorphone</time_frame>
        <population>One 25 mcg patient is missing data on this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation, Need for Supplemental Oxygen</title>
          <description>Intravenously, and to a lesser extent, intrathecally administered opioids can lead to respiratory depressions. Therefore the subjects' oxygen saturation is measured (standard clinical practice).</description>
          <population>One 25 mcg patient is missing data on this outcome</population>
          <units>percentage oxygenated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" spread="1.49"/>
                    <measurement group_id="O2" value="99.0" spread="0.87"/>
                    <measurement group_id="O3" value="98.4" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Nausea and Vomiting Requiring Rescue Medication</title>
        <description>IV and IT opioids can induce nausea and vomiting. Outcome measure is reported as percentage of patients with nausea and vomiting requiring rescue medication.</description>
        <time_frame>24hrs post administration of IT hydromorphone</time_frame>
        <population>One 25 mcg patient was missing data on this measure</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Nausea and Vomiting Requiring Rescue Medication</title>
          <description>IV and IT opioids can induce nausea and vomiting. Outcome measure is reported as percentage of patients with nausea and vomiting requiring rescue medication.</description>
          <population>One 25 mcg patient was missing data on this measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hypothermia (Body Temperature &lt; 95F/35C)</title>
        <description>intrathecally administered opioids can cause hypothermia (body temperature &lt;95F/35C)</description>
        <time_frame>24hrs post administration of IT hydromorphone</time_frame>
        <population>One 25 mcg patient was missing data on this measure</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hypothermia (Body Temperature &lt; 95F/35C)</title>
          <description>intrathecally administered opioids can cause hypothermia (body temperature &lt;95F/35C)</description>
          <population>One 25 mcg patient was missing data on this measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Visual Disturbances</title>
        <description>IT/IV opioids can create visual disturbances. The number of patients with visual disturbances are reported.</description>
        <time_frame>24hrs post administration of IT hydromorphone</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Visual Disturbances</title>
          <description>IT/IV opioids can create visual disturbances. The number of patients with visual disturbances are reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Pruritus</title>
        <description>IT opioids can cause pruritus. Persistent pruritus requiring treatment will be recorded.</description>
        <time_frame>24hrs post administration of IT hydromorphone</time_frame>
        <population>One 25 mcg patient is missing data on this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Pruritus</title>
          <description>IT opioids can cause pruritus. Persistent pruritus requiring treatment will be recorded.</description>
          <population>One 25 mcg patient is missing data on this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative Vasopressor Use: Ephedrine Equivalents</title>
        <description>IT (intrathecal) applied local anesthetics and opioids can cause arterial and venous vasodilation leading to a decrease in afterload as well as preload. This is typically treated with volume replacement and vasopressors (acutely). Total intraoperative vasopressor use will be reported for ephedrine equivalents.</description>
        <time_frame>Intraoperatively (at time of operation)</time_frame>
        <population>One 25 mcg patient is missing data on this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Vasopressor Use: Ephedrine Equivalents</title>
          <description>IT (intrathecal) applied local anesthetics and opioids can cause arterial and venous vasodilation leading to a decrease in afterload as well as preload. This is typically treated with volume replacement and vasopressors (acutely). Total intraoperative vasopressor use will be reported for ephedrine equivalents.</description>
          <population>One 25 mcg patient is missing data on this outcome</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.98" spread="26.94"/>
                    <measurement group_id="O2" value="56.48" spread="32.27"/>
                    <measurement group_id="O3" value="45.48" spread="19.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative Vasopressor Use: Phenylephrine Equivalents</title>
        <description>IT (intrathecal ) applied local anesthetics and opioids can cause arterial and venous vasodilation leading to a decrease in afterload as well as preload. This is typically treated with volume replacement and vasopressors (acutely).
Total intraoperative vasopressor use will be reported for phenylephrine equivalents.</description>
        <time_frame>Intraoperatively (at time of operation)</time_frame>
        <population>One 25 mcg patient is missing data on this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone 25mcg</title>
            <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 50mcg</title>
            <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 100mcg</title>
            <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Vasopressor Use: Phenylephrine Equivalents</title>
          <description>IT (intrathecal ) applied local anesthetics and opioids can cause arterial and venous vasodilation leading to a decrease in afterload as well as preload. This is typically treated with volume replacement and vasopressors (acutely).
Total intraoperative vasopressor use will be reported for phenylephrine equivalents.</description>
          <population>One 25 mcg patient is missing data on this outcome</population>
          <units>mcg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751.04" spread="331.76"/>
                    <measurement group_id="O2" value="695.54" spread="397.42"/>
                    <measurement group_id="O3" value="560.11" spread="243.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hydromorphone 25mcg</title>
          <description>The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 25mcg: Intrathecal Hydromorphone 25mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
        <group group_id="E2">
          <title>Hydromorphone 50mcg</title>
          <description>The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 50mcg: Intrathecal Hydromorphone 50mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
        <group group_id="E3">
          <title>Hydromorphone 100mcg</title>
          <description>The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
Hydromorphone 100mcg: Intrathecal Hydromorphone 100mcg
spinal anesthesia: bupivacaine 0.75% 1.6 mL (12mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dirk J Varelmann, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-8280</phone>
      <email>dvarelmann@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

